LanZhou Foci Pharmaceutical Co.,Ltd. (SZSE: 002644)
Health Care · Pharmaceuticals · CN
CN¥8.20
-3.42% today · -13.0% 1Y
LanZhou Foci Pharmaceutical Co.,Ltd. (SZSE: 002644) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $622.90M and employs 1,332 people.
Over the last twelve months the share price has lost 13.0%, trading between 6.63 and 11.02.
Tweenvest scores LanZhou Foci Pharmaceutical Co.,Ltd. across four factors: quality 74/100, value 54/100, growth 43/100, dividend 6/100. Its strongest factor is quality.
002644 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $622.90M
- Revenue (TTM)
- $136.39M
- P/E
- 71.17
- EPS
- 0.12
- Dividend yield
- 0.24%
- Beta (5Y)
- 0.19
- 52-week high
- CN¥11.02
- 52-week low
- CN¥6.63
- Avg volume (3M)
- —
- Shares outstanding
- 510.66M
- Employees
- 1,332
- Next earnings
- —
About LanZhou Foci Pharmaceutical Co.,Ltd.
LanZhou Foci Pharmaceutical Co.,Ltd. is a prominent pharmaceutical entity based in China, primarily focused on the manufacturing and distribution of traditional Chinese medicines. Its diverse product line, offered under the "Min Shan" and "Foci" brand names, encompasses a variety of formats, including pills, tablets, capsules, and granules. Beyond its production activities, the company actively pursues research and development initiatives aimed at pioneering novel herbal remedies. Its global footprint extends to approximately 27 countries, with key export markets including the United States, Canada, Japan, Australia, Russia, Ukraine, Singapore, Indonesia, Thailand, Malaysia, New Zealand, and Hong Kong. Established in 1929, the firm's headquarters are located in Lanzhou, China. LanZhou Foci Pharmaceutical Co.,Ltd. operates as a subsidiary of the Lanzhou Foci Pharmaceutical Factory.
- ISIN
- CNE1000019W4
- Founded
- 1929
- Listed since
- Dec 22, 2011
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,257.00 | +0.13% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.37 | +0.42% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $153.38 | +0.54% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.90 | -1.25% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.48 | -0.76% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.13 | +0.21% |
Figures last refreshed Aug 18, 2026.